AstraZeneca Signed ~$402M Exclusive Worldwide License Agreement with C4XD to Develop and Commercialize NRF2 Activator Program
Shots:
- C4XD is eligible to receive ~$16M pre-clinical milestones fees for the first clinical trial incl. $2M up front and is also eligible to receive $385.8M in clinical development and commercial milestones along with royalties
- AstraZeneca will be responsible to develop and commercialize an oral therapy for the treatment of inflammatory and respiratory diseases with an initial focus on COPD
- The agreement adds new assets to AstraZeneca’s portfolio & targets underlying disease drivers to modify the course of the diseases. The agreement further supports C4XD's scientific expertise and strategy through the third deal with the pharmaceutical company
Ref: Globenewswire | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
